Our results demonstrate for the first time that FPRL2 is highly expressed in breast cancer and adriamycin-resistant breast cancer cells and that knockdown of FPRL2 increases adriamycin-induced apoptosis in breast cancer cells. Here, FPR3 is linked to breast carcinoma.